bimiralisib

Drug Overview

Bimiralisib (also known in research as PQR309) is a highly advanced, investigational medication designed to fight cancer. It belongs to a modern group of medicines called Targeted Therapy. Unlike traditional chemotherapy that attacks all fast-growing cells, bimiralisib acts as a “Smart Drug.” It is built to find and block specific broken signals inside cancer cells that tell the tumor to grow and spread.

Currently, bimiralisib is not available at regular pharmacies. It is being carefully tested in global clinical trials to see how well it works for patients with stubborn blood cancers, advanced solid tumors, and certain pre-cancerous skin conditions. Notably, this drug is unique because it can easily cross the “blood-brain barrier,” making it a strong candidate for treating brain tumors.

Generic Name: Bimiralisib (Investigational code: PQR309)
US Brand Names: None (Currently an investigational drug)
Drug Class: Dual pan-PI3K and mTOR inhibitor
Route of Administration: Oral (taken by mouth as a capsule) and Topical (applied to the skin as a gel)
FDA Approval Status: Investigational (Not yet approved by the FDA; currently in Phase I and Phase II clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Smart Drug works, imagine a cancer cell as a factory. The factory relies on a specific power line to keep the machines running and the cell multiplying. In many cancers, this power line is called the PI3K/AKT/mTOR pathway.

When this pathway is broken or mutated, the power is stuck in the “ON” position, causing the cancer to grow out of control.

At the molecular level, bimiralisib works by shutting down this power line completely:

The Dual Blocker: Older targeted drugs only blocked one part of the pathway (either PI3K or mTOR). The cancer cells were smart and would quickly find a detour around the block. Bimiralisib is a “dual inhibitor.” It blocks both the PI3K proteins (all class I types) and the mTOR proteins (mTORC1 and mTORC2) at the same time.
Plugging the ATP Pocket: It works by perfectly fitting into the “ATP-binding pocket” of these proteins. ATP is the energy source the proteins need to send their growth signals. By plugging this pocket, the drug cuts off their energy.
Stopping the Growth Cycle: Without these signals, the cancer cell gets stuck in the “G1 phase” (a resting stage) and cannot copy its DNA.
Triggering Cell Death: Because the cancer cell is starved of its growth signals, it eventually gives up and triggers a natural self-destruct process called apoptosis.

FDA-Approved Clinical Indications

Because bimiralisib is still an investigational medication, it does not have official FDA-approved uses yet. However, based on current clinical trials, it is being tested for the following conditions:

Oncological Uses (Under Investigation)

Relapsed or Refractory Lymphomas: Blood cancers that have come back after past treatments.
Advanced Solid Tumors: Including breast cancer, ovarian cancer, and head and neck squamous cell carcinomas (HNSCC) that carry specific gene mutations (like NOTCH1).
Glioblastoma: An aggressive type of brain cancer.
Acute Myeloid Leukemia (AML): Specifically studied in combination with other drugs for patients with IDH2 and FLT3 genetic mutations.

Non-Oncological Uses (Under Investigation)

Actinic Keratosis: A pre-cancerous skin condition caused by sun damage. (A topical gel form of the drug is used for this).

Dosage and Administration Protocols

Note: Because bimiralisib is an investigational drug, dosages are determined strictly by clinical trial protocols. The table below shows the schedules used in recent Phase I and Phase II human trials.

Protocol Detail	Standard Trial Dose	Frequency	Administration Notes
Oral (Continuous Schedule)	80 mg	Once daily	Swallowed whole with water.
Oral (Intermittent Schedule)	140 mg	2 days a week	Used to give the body a rest and lower side effects.
Topical Gel (For Skin)	2% concentration	Once daily	Applied directly to the affected skin area.

Dose Adjustments:

Hepatic (Liver) Insufficiency: Because this drug is processed by the liver and can affect metabolism, trial doctors monitor liver function closely. The dose is usually lowered if the liver shows signs of stress.
Renal (Kidney) Insufficiency: No specific starting dose adjustments are widely standardized yet, but blood tests are required to ensure the kidneys remain healthy.

Clinical Efficacy and Research Results

Recent clinical research (spanning 2020 to 2025) has provided important data on both the oral pill and the skin gel versions of bimiralisib.

Blood Cancers (Lymphoma): In a 2021-2022 Phase II trial for heavily pre-treated lymphoma patients, the continuous 80 mg oral dose showed modest results. The Overall Response Rate (ORR) was 14%, meaning the tumors shrank in a small group of patients, while another 36% of patients saw their disease stabilize and stop growing.
Skin Conditions Breakthrough (2025): In late 2025, a Phase II trial testing the 2% topical gel for actinic keratosis showed remarkable success. 92% of patients with mild lesions achieved complete or near-complete clearance of their pre-cancerous spots, making it a highly promising future treatment.
Combination Therapies: Researchers found that combining bimiralisib with another drug called venetoclax greatly increases the cancer-killing effect in acute myeloid leukemia (AML) patients, potentially extending survival times.

Safety Profile and Side Effects

Like all powerful cancer medicines, bimiralisib can cause side effects. Because it changes how the body uses energy and sugar, it has a very specific safety profile.

Black Box Warning:

As an investigational drug, bimiralisib does not currently carry an FDA Black Box Warning.

Common Side Effects (>10%)

Hyperglycemia (High Blood Sugar): This is the most common side effect (affecting up to 44% to 76% of oral pill users), because the PI3K pathway also controls how the body processes insulin.
Fatigue: Feeling unusually tired or weak (around 50%).
Gastrointestinal Upset: Diarrhea, nausea, and vomiting.
Decreased Appetite and Weight Loss.
Cytopenias: Drops in blood cells, including low white blood cells (neutropenia) and low platelets (thrombocytopenia).

Serious Adverse Events

Severe Hyperglycemia: Extremely high blood sugar that requires the patient to start taking diabetes medications or insulin.
Severe Infections: Due to low white blood cell counts, patients are at a higher risk of catching serious infections.

Management Strategies

For High Blood Sugar: Doctors will check your blood sugar levels regularly. Many patients in trials are given standard oral diabetes pills (like metformin) to keep their blood sugar safe while taking the cancer drug.
Using Intermittent Schedules: To manage severe fatigue and blood sugar spikes, researchers are moving toward “intermittent dosing” (taking the pill only 2 days a week). This schedule has proven to be much safer while keeping the cancer-fighting benefits.

Connection to Stem Cell and Regenerative Medicine

Research Areas: Bimiralisib is currently a major focus in the study of Cancer Stem Cells. Tumors often have a small group of stubborn “root cells” (cancer stem cells) that survive standard chemotherapy and cause the cancer to grow back years later. These dangerous stem cells rely heavily on the PI3K/mTOR pathway to survive. By using a dual-inhibitor like bimiralisib, scientists are attempting to target and destroy these roots permanently. This could prevent the cancer from regenerating, offering a much more permanent cure when combined with other regenerative or immune therapies.

Patient Management and Practical Recommendations

If you are participating in a clinical trial using bimiralisib, your healthcare team will monitor you very closely.

Pre-treatment Tests to be Performed

Fasting Blood Glucose and HbA1c: To check your baseline blood sugar and screen for hidden diabetes.
Complete Blood Count (CBC): To ensure your red blood cells, white blood cells, and platelets are healthy enough before starting.
Comprehensive Metabolic Panel (CMP): To check liver and kidney function.

Precautions During Treatment

Dietary Monitoring: You may need to follow a low-sugar, balanced diet to help prevent severe spikes in your blood glucose.
Infection Risks: Wash your hands frequently and avoid large crowds, as your immune system may be temporarily weakened.

“Do’s and Don’ts” List

Do buy a home blood sugar monitor if your trial doctor recommends it, and track your levels daily.
Do tell your doctor immediately if you feel extremely thirsty, need to urinate very often, or have blurry vision (these are signs of dangerously high blood sugar).
Do take the pill exactly as prescribed. If you are on an intermittent schedule, use a calendar to track your specific “on” and “off” days.
Don’t take any over-the-counter herbal supplements without asking your research nurse, as they can interfere with how your liver processes the drug.
Don’t ignore a fever. If your temperature goes over 100.4°F (38°C), contact your clinic right away.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only. Bimiralisib (PQR309) is an investigational drug and is not approved by the U.S. Food and Drug Administration (FDA) or other global regulatory agencies for standard commercial use. It is only available to patients enrolled in approved clinical trials. This information should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your oncologist or a qualified healthcare provider regarding your specific medical condition, treatment options, and clinical trial eligibility.